Küçük Lab. on Lymphoid Cancer Genomics

RESEARCH INTERESTS

ur current research mainly focuses on the identification and characterization of novel mutations and epigenetic alterations of tumor suppressor genes or oncogenes in lymphoid cancers. Our interest mainly resides in lymphomas (e.g. follicular lymphoma) and other lymphoid cancers (e.g. multiple myeloma) which are neoplastic diseases having a high degree of genetic heterogeneity.

We frequently use next generation sequencing (NGS) based technologies (e.g. WES, RNA-Seq, targeted NGS) to generate a candidate list of aberrant genes using panels of lymphoma patient samples. We then cross-validate mutations that are identified through NGS methodologies by applying Sanger sequencing. Moreover, our studies focus on genome-wide or loci-specific methylation changes in cancer samples. Altogether, we characterize these aberrations using a combination of genetic, epigenetic and molecular biology assays. In general, our studies follow a wholistic approach which involves the cooperation of a variety interrelated biomedical disciplines such as pathology, functional genomics, and computational bioinformatics. Our eventual goal is to identify and characterize genetic and epigenetic abnormalities in individual cancer patients to translate the discoveries as personalized medicine.

Selected Publications

Wan Y, He D, Ye Y, Zhang W, Zhao S, Long Y, Chen M, Küçük C. Primary cardiac diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression in an immunocompetent Chinese elderly woman. Cardiovasc Pathol.. 2017 Nov ; 31 54-56. doi:10.1016/j.carpath.2017.07.006.

Hu X, Baytak E, Li J, Akman B, Okay K, Hu G, Scuto A, Zhang W, Küçük C. The relationship of REL proto-oncogene to pathobiology and chemoresistance in follicular and transformed follicular lymphoma. Leuk Res.. 2017 Mar ; 54 30-38. doi:10.1016/j.leukres.2017.01.001.

Baytak E, Gong Q, Akman B, Yuan H, Chan WC, Küçük C. Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1. Tumour Biol.. 2017 May ; 39 (5): 1,01043E+15. doi:10.1177/1010428317701648.

Awards

  • Can KÜÇÜK - Young Investigator (GEBİP) Awards by Turkish Academy of Sciences (TÜBA), 2017
  • Can KÜÇÜK - Global Research Award by American Society of Hematology, 2018

Contact

Küçük Lab. on Lymphoid Cancer Genomics

Group Leader

Can KUCUK
can.kucuk@ibg.edu.tr
+90 232 299 41 00 (5011)
+9 02322994151